Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
318 Results for "
microenvironment
" in MedChemExpress (MCE) Product Catalog:
Products (318)
318 Results for "microenvironment" in MCE Product Catalog:
Cat. No.: HY-184162
CAS No.: 2991567-27-0
HSP110-IN-1 is a HSP110 inhibitor. HSP110-IN-1 binds to HSP110, inhibits the activity of STAT3, and downregulates the expression of downstream genes VEGF, MMP7 and MMP9. HSP110-IN-1 abrogates IL-6-induced epithelial-mesenchymal transition and inhibits the proliferation of colorectal cancer cells. HSP110-IN-1 remodels the tumor microenvironment by inducing a pro-inflammatory phenotype, regulates macrophages, induces PD-L1 expression, and enhances anti-PD-L1 antibody-mediated tumor regression. HSP110-IN-1 can be used in studies related to colorectal cancer .
Cat. No.: HY-188081
CAS No.: 3112733-78-2
Target:
Research Areas:
YH-36400 is an orally bioavailable inhibitor of HIF-1α and HIF-2α. YH-36400 disrupts the dimerization of HIF-1α and HIF-1β and triggers proteasomal degradation, thereby inhibiting the transcriptional activities of HIF-1 and HIF-2. YH-36400 reduces the expression of PD-L1 and CD73, reprograms the tumor immune microenvironment, inhibits angiogenesis, and can be used in combination with immune checkpoint blockade therapy. YH-36400 is applicable to research related to breast cancer, lung cancer, melanoma, pancreatic cancer, colorectal cancer, prostate cancer, and head and neck squamous cell carcinoma .
Cat. No.: HY-D1450
CAS No.: 155613-98-2
Synonyms: S01448
Target:
Research Areas:
IR-1048 is a nitroreductase (NTR)-responsive near-infrared fluorescence (NIR)/photoacoustic (PA) imaging probe and photothermal agent. IR-1048 is coupled with a nitroimidazole group to form IR-1048-MZ. IR-1048-MZ is catalytically reduced by NTR in a hypoxic environment, restoring strong near-infrared absorption and fluorescence emission (NIR II window), while activating the photothermal effect. IR-1048 relies on NTR-mediated electron transfer to relieve intramolecular fluorescence quenching, achieving specific imaging and photothermal ablation of tumor hypoxic areas. IR-1048 is mainly used for high-contrast NIR II/photoacoustic imaging and photothermal therapy research and tumor diagnosis of the tumor hypoxic microenvironment .
Cat. No.: HY-D3351
CAS No.: 2668963-61-7
Target:
Research Areas:
PNO1 is a fluorescent probe for pulmonary fibrosis detection. The detection mechanism of PNO1 relies on sensing upregulated nitric oxide (NO) in the pulmonary fibrosis (PF) microenvironment. PNO1 contains an aniline group that reacts with NO or its derivatives under acidic conditions to form an N-nitrosylated intermediate, which is subsequently converted into a diazonium salt and undergoes deamination, eliminating the intramolecular electron transfer quenching effect and triggering a fluorescence turn-on response. The excitation wavelength of PNO1 includes 545 nm in in vitro solution studies, while an excitation range of 520-550 nm is used for cell, tissue and in vivo imaging; its emission wavelength centers at 572 nm in the unreacted state, and shifts to 559 nm with enhanced fluorescence intensity upon binding to NO. PNO1 can be used for pulmonary fibrosis research .
Cat. No.: HY-N2452
CAS No.: 956103-79-0
Target:
Cat. No.: HY-N3387
CAS No.: 30508-27-1
Cat. No.: HY-P992454
Cat. No.: HY-P992511
Target:
Research Areas:
Cat. No.: HY-L025
11,237 compounds
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc.
MCE designs a unique collection of 11,237 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.
Cat. No.: HY-179626
CAS No.: 2138299-66-6
Target:
Research Areas:
STING agonist-49 (Compound 1) is a STING agonist and can be used as a payload for ADCs. STING agonist-49 can be applied in lung cancer research .
Cat. No.: HY-181919
Research Areas:
CD73-IN-22 (Compound HX-6) is a non-nucleoside CD73 inhibitor with an IC50 of 0.07 μM. When radiolabeled with 68Ga, CD73-IN-22 acts as a PET radiotracer for detecting CD73 expression. When radiolabeled with 177Lu, CD73-IN-22 exhibits anticancer activity against colorectal adenocarcinoma. CD73-IN-22 is applicable to research related to colon adenocarcinoma and breast cancer .
Cat. No.: HY-168954
CSF1R-IN-26 (Compound III-1) is the inhibitor for CSF-1R with an IC50 of 20.07 nM. CSF1R-IN-26 promotes the polarization of M2 macrophages to M1 macrophages, thereby inducing apoptosis in MC-38 cancer cell. CSF1R-IN-26 inhibits the activation of AKT/ERK/STAT3 signaling pathway. CSF1R-IN-26 reconstructs the tumor immune microenvironment and exhibits antitumor activity in mouse models. CSF1R-IN-26 exhibits pharmacokinetics characteristics in SD rats with a half-life 1.86 hours, and an oral bioavailability of 79.22% .
Cat. No.: HY-175660
Target:
Research Areas:
KCL-HO-1i is an orally active heme oxygenase-1 (HO-1) inhibitor (rat HO-1: IC50 = 123 nM) and human HO-1: IC50 = 128 nM). KCL-HO-1i targets immunosuppressive LYVE-1 + perivascular tumor-associated macrophages (PvTAMs) in the tumor microenvironment (TME), reduces PvTAM-mediated immune exclusion. KCL-HO-1i demonstrates synergistic anti-tumor efficacy with chemotherapy in MMTV-PyMT spontaneous breast cancer mice or C57Bl/6 mice bearing subcutaneous MN-MCA1 sarcomas. KCL-HO-1i can be used for the study of cancer .
Cat. No.: HY-181877
Target:
Research Areas:
IHCH-3185 is an orally active class I HDAC inhibitor (HDAC1 IC50 =102.9 nM) and A2AR antagonist (A2AR Ki =7.6 nM). IHCH-3185 reverses immune gene silencing by inducing histone acetylation and blocks the adenosine signaling pathway to relieve T-cell suppression. IHCH-3185 exhibits antiproliferative activity, induces cell cycle arrest, and significantly improves the tumor microenvironment. IHCH-3185 reduces the proportion of regulatory T cells, increases the CD8 +/Treg ratio, and upregulates the expression of key factors such as H2-K1, Cxcl9 and Cxcl10. IHCH-3185 shows significant antitumor potential in CT26 and MC38 mouse tumor models and is suitable for related cancer research .
Cat. No.: HY-P2632
CAS No.: 289042-25-7
Synonyms: RADA16
Target:
Research Areas:
Cat. No.: HY-W048825
CAS No.: 87512-31-0
Target:
Research Areas:
Cat. No.: HY-182988
CAS No.: 2681258-65-9
L-Arg-DSPE is an arginine-functionalized DSPE lipid containing free guanidine groups. L-Arg-DSPE serves as a component of NO-responsive degradable drug-loaded liposomal nanomotors (L-Arg@Lip-DOX), promoting drug deep tumor tissue penetration and cellular internalization. L-Arg-DSPE can be used for the research of drug delivery .
Cat. No.: HY-P992517
Target:
Research Areas:
Cat. No.: HY-172934
Research Areas:
FGT-4 is a FR-β-targeted chimeric molecule. FGT-4 acts as a TLR7 agonist. FGT-4 binds to FR-β to enable delivery to tumor-associated macrophages and myeloid-derived suppressor cells. FGT-4 promotes the secretion of iNOS (associated with M1 macrophages) and the pro-inflammatory cytokine IL-6, and enhances the proliferation of cytotoxic CD8+ T cells. FGT-4 can be used for the research of breast cancer .
Cat. No.: HY-174485
Target:
Research Areas:
OVA mRNA (N1-Me-Pseudo UTP) is an mRNA encoding chicken ovalbumin. The substitution with N1-Me-Pseudo UTP (m1Ψ) improves protein expression and reduces innate immune response. OVA mRNA binds to the STING-activating polymer PD18 and is encapsulated in optimized lipid nanoparticles to construct an mRNA vaccine platform (PD18 LNP). This platform not only enhances the lymphatic delivery efficiency and protein expression of mRNA, but also potently adjuvates immune responses via activating the STING pathway .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
